Home > Oncology > WCLC 2022 > WCLC 2022 Congress Round-Up > First DLL3-targeted therapy shows promise in SCLC

First DLL3-targeted therapy shows promise in SCLC

Presented By
Prof. Hossein Borghaei, Fox Chase Cancer Center, PA, USA
Conference
WCLC 2022
Trial
Phase 1
Doi
https://doi.org/10.55788/a77cbb9d
Tarlatamab, the first delta-like ligand 3 (DLL3)-targeted immune therapy, demonstrated encouraging anti-tumour activity and an acceptable safety profile in patients with heavily pre-treated small cell lung cancer (SCLC). The results of the current phase 1 trial initiated the development of the phase 2 DeLLphi-301 study, analysing tarlatamab in patients with SCLC who received at least 2 prior lines of therapy [1]. “The treatment options for patients with pre-treated SCLC are limited,” stated Prof. Hossein Borghaei (Fox Chase Cancer Center, PA, USA). “Therefore, novel therapies are urgently needed for these patients.” Tarlatamab is a bispecific T cell-engager immune therapy that binds both DLL3 and CD3 [2]. The first-in-human study of tarlatamab evaluated this agent in 106 patients with SCLC who progressed on at least 1 platinum-based chemotherapy regimen. Safety was the primary outcome of this trial, in which patients received tarlatamab doses of up to 100 ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on